溴己新辅助地塞米松治疗分泌性中耳炎患者的疗效观察

Efficacy of bromhexine adjuvant to dexamethasone in the treatment of patients with secretory otitis media

目的:研究溴己新辅助地塞米松治疗分泌性中耳炎患者的临床疗效。方法:选取2019年1月至2020年3月我院95例分泌性中耳炎(Secretory otitis media,SOM)患者,随机分两组,除常规治疗外,对照组(47例)予以地塞米松治疗,研究组(48例)予以溴己新辅助地塞米松治疗,比较两组疗效、6个月内复发率,治疗前、治疗1周后听力水平与鼓室压,血清炎性因子[白介素-8(Interleukin-8,IL-8)与白介素-1β(Interleukin-1β,IL-1β)]与转化生长因子[转化生长因子-β1(Transforming growth factor-β1,TGF-β1)与转化生长因子-β2(Transforming growth factor-β2,TGF-β2)]水平。结果:治疗1周后,研究组总有效率91.67%高于对照组74.47%(P<0.05);治疗1周后研究组0.5 kHz、1.0 kHz、2.0kHz频率下听力水平与鼓室压均高于对照组(P<0.05);治疗1周后研究组血清IL-8、IL-1β与TGF-β1、TGF-β2水平均低于对照组(P<0.05);研究组6个月内复发率4.65%低于对照组23.53%(P<0.05)。结论:溴己新辅助地塞米松治疗SOM患者,可降低血清炎性因子与转化生长因子,明显改善患者听力水平,降低复发率,提高整体治疗效果。

Objective:To analyze the clinical efficacy of bromhexine adjuvant to dexamethasone in the treatment of patients with secretory otitis media.Methods:From January 2019 to March 2020,95 Secretory otitis media(SOM)patients in our hospital were selected and divided into 2 groups by random number table method.The control group(47 cases)was treated with dexamethasone,and the research group(48 cases)was treated with bromhexine adjuvant to dexamethasone.Before and after treatment,the efficacy,recurrence rate within 6 months,hearing level and tympanum pressure were compared between the two groups.Serum inflammatory cytokines[Interleukin-8(IL-8)and interleukin-1β(IL-1β)]and transforming growth factor[transforming growth factor-β1(TGF-β1)and transforming growth factor-β2 TGF-β2]levels.Results:After one week of treatment,the total effective rate of the study group was 91.67%higher than that of the control group(74.47%)(P<0.05).After treatment,the hearing level and tympanic pressure in the study group at frequencies of 0.5kHz,1.0kHz and 2.0kHz were higher than those in the control group(P<0.05).After treatment,the levels of serum IL-8,IL-1β,TGF-β1,TGF-β2 in the study group were lower than those in the control group(P<0.05).The recurrence rate within 6 months in the study group was 4.65%lower than 23.53%in the control group(P<0.05).Conclusion:Bromhexine adjuvant to dexamethasone in the treatment of patients with SOM reduces serum inflammatory factors and transforming growth factors,significantly improve the hearing level of patients,reduce the recurrence rate,and improve the overall therapeutic effect.